Results Presented for Idelalisib in Refractory Indolent Non-Hodgkin's Lymphoma Monthly Prescribing Reference Gilead announced results from the Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K delta, for the treatment of patients with indolent non-Hodgkin's lymphoma (iNHL) that is refractory (non-responsive) to ... Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent ... Gilead Announces Pivotal Phase 2 Results For Idelalisib In Refractory iNHL |
